reports
- Jonathan Moreland
XOMA XOMA
SMRTQ STEIN MART INC.
GTIM GOOD TIMES RESTAURANTS INC
CYTR CYTRX CORPORATION
CRMD CORMEDIX INC.
AGRX AGILE THERAPEUTICS
HTBI HOMETRUST BANCSHARES INC
TACO TACO CABANA INC.
PRVB PROVENTION BIO INC
RRR RSC HOLDINGS
VEL INC.
EVF VELOCITY COMPOSITES
EATON VANCE SENIOR INCOME TRUST
- MarketLine Department
Insider bought: A director bought 2,325,581 shares at 0.430USD and
A director at Cytrx Corp bought 2,325,581 shares at 0.430USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
24-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investo...
BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith reminds investors of the upcoming September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired CytRx Corporation (“CytRx” or the “Company”) (NASDAQ: CYTR) securities between November 18, 2014 and July 11, 2016, inclusive (the “Class Period”). CytRx investors have until September 23, 2016 to file a lead plaintiff motion. The Complaint alleges that throughout the Class Perio...
GPM Reminds Investors of the September 23rd Deadline in the Class Acti...
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise acquired CytRx Corporation (“CytRx” or the “Company”) (NASDAQ: CYTR) securities between November 18, 2014 and July 11, 2016, inclusive (the “Class Period”). CytRx investors have until September 23, 2016 to file a lead plaintiff motion. The Complaint alleges that throughout the Class Peri...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of CytRx Co...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation (“CytRx” or the “Company”) (NASDAQ:CYTR) between November 18, 2014 and July 11, 2016. You are hereby notified that a securities class action has commenced in the USDC for the Central District of California. If you purchased or otherwise acquired CytRx securities between November 18, 2014 and July 11, 2016, your rights may be affec...
Update: Cardiac safety data support investment case
CytRx released cardiotoxicity data and interim positive efficacy results from the Phase II GBM and combination Phase Ib aldoxorubicin studies. Our focus remains on the ongoing Phase III second-line soft tissue sarcoma (STS) trial, with data expected in H216. While our fundamental view on the drug’s potential has not changed, the supplied cardiotoxicity data supports its intended mechanism of action. That is, by acting as a safer form of doxorubicin, aldoxorubicin may displace it in STS and pot...
Update: Preparing to go solo in the US on aldoxorubicin
As it advances lead candidate aldoxorubicin through clinical trials, CytRx is also planning to commercialise the oncology drug through a specialty sales force in the US, rather than go through traditional biotech drug out-licensing deals in this market. We are revising our assumptions to consider the prospect of CytRx capturing full US aldoxorubicin economics, which raises our rNPV to $375m (from $209m previously).
Update: Aldoxorubicin trials resume as clinical hold lifted
The lifting of a partial clinical hold imposed on aldoxorubicin improves clarity on its future development and enables the firm to maintain its existing timeline projections for the ongoing clinical trials. CytRx is confident its funds on hand should be sufficient to reach top-line data in mid-2016 from its Phase III study in second-line soft tissue sarcoma (STS).
Update: Partial clinical hold a minor setback
Aldoxorubicin’s randomised clinical trials (RCTs) were placed under a partial clinical hold following the death of a patient with metabolic acidosis who received the drug on a compassionate-use basis and did not qualify for any of the RCTs. CytRx believes this was the only case of metabolic acidosis out of >250 patients who received the drug to date. While already-enrolled patients can continue receiving the drug, no new patients can be dosed until the hold is lifted. CytRx is amending the pro...
Update: Detailed results on aldoxorubicin presented
Detailed results of the Phase IIb trial of aldoxorubicin in first-line STS patients presented at the annual meeting of ASCO (top-line results were reported in several press releases) continue to show the drug's superior efficacy and safety profile over doxorubicin. The 400-patient, FDA SPA-sanctioned Phase III trial in second-line STS is progressing well with targeted completion of accrual in 2015 and possible top-line readout in 2016, a major value inflection point if the data are positive.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.